

World Journal of *Hematology*

World J Hematol 2013 February 6; 2(1): 1-5





World Journal of Hematology

A peer-reviewed, online, open-access journal of hematology

Editorial Board

2012-2016

The *World Journal of Hematology* Editorial Board consists of 123 members, representing a team of worldwide experts in hematology. They are from 29 countries, including Argentina (2), Austria (1), Belgium (1), Brazil (1), Canada (1), China (4), Croatian (1), Denmark (1), France (6), Germany (4), Greece (4), India (1), Iran (1), Ireland (1), Israel (2), Italy (11), Japan (9), Luxembourg (1), Mexico (1), Netherlands (7), Norway (2), Romania (1), Singapore (1), South Korea (2), Spain (6), Thailand (1), Turkey (5), United Kingdom (9), and United States (36).

EDITOR-IN-CHIEF

Xiaoyan Jiang, *Vancouver*
Thomas J Kipps, *San Diego*

GUEST EDITORIAL BOARD MEMBERS

Hwei-Fang Tien, *Taipei*

MEMBERS OF THE EDITORIAL BOARD



Argentina

Ricardo Forastiero, *Buenos Aires*
Mirta A Schattner, *Buenos Aires*



Austria

Richard H Moriggl, *Vienna*



Belgium

Xavier Sagaert, *Leuven*



Brazil

Constantino José Fernandes Jr, *São Paulo*



China

Anskar YH Leung, *Hong Kong*
Raymond HS Liang, *Hong Kong*
Xiao-Yu Tian, *Hong Kong*



Croatian

Mariastefania Antica, *Zagreb*



Denmark

Erik Lerkevang Grove, *Aarhus*



France

Emmanuel Andres, *Strasbourg*
Claude Bagnis, *Marseille*
Bernard Binetruy, *Marseille*
Cyril Fauriat, *Marseille*
Florence Nguyen Khac, *Paris*
Xavier Georges Thomas, *Pierre Benite*



Germany

Arnold Ganser, *Hannover*
Dirk Matthias Hermann, *Essen*
Rory R Koenen, *Munich*
Zhixiong Li, *Hannover*



Greece

Anastasios G Kriebardis, *Athens*
Marie-Christine Kyrtsonis, *Athens*
Gerassimos A Pangalis, *Athens*
Issidora S Papassideri, *Athens*



India

Gurudutta U Gangenahalli, *Delhi*



Iran

Shahram Teimourian, *Tehran*



Ireland

Eva Szegezdi, *Galway*



Israel

Jacob George, *Rehovot*
Avichai Shimoni, *Tel-Hashomer*



Italy

Luca Arcaini, *Pavia*
Vincenzo Casolaro, *Baronissi*
Alessia Colosimo, *Teramo*
Raimondo De Cristofaro, *Rome*
Claudio Fozza, *Sassari*
Edoardo G Giannini, *Genova*
Giampiero La Rocca, *Palermo*
Pier Paolo Piccaluga, *Bologna*
Alessandro Poggi, *Genoa*
Sergio M Siragusa, *Palermo*
Elena Zocchi, *Genova*



Japan

Xian Wu Cheng, *Nagoya*
Seiji Fukuda, *Izumo*
Satoshi Hagiwara, *Yufu*
Shinsaku Imashuku, *Takasago*
Masanobu Kitagawa, *Tokyo*
Tetsuya Nosaka, *Tsu*

Masao Seto, *Nagoya*
Toshiki Shimizu, *Moriguchi*
Masafumi Takahashi, *Shimotsuke*



Luxembourg

Jacques Zimmer, *Luxembourg*



Mexico

Agustin Avilés, *Mexico City*



Netherlands

Miranda Buitenhuis, *Rotterdam*
Roland P Kuiper, *Nijmegen*
Jan Jacques Michiels, *Erasmus*
Gerry AF Nicolaes, *Maastricht*
Pieter Sonneveld, *Rotterdam*
Arnold Spek, *Amsterdam*
Ruurd Torensma, *Nijmegen*



Norway

Brynjar Foss, *Stavanger*
Mikhail Sovershaev, *Tromsø*



Romania

Adriana Georgescu, *Bucharest*



Singapore

Jerry Chan, *Singapore*



South Korea

Jung Weon Lee, *Seoul*
Myung-Geun Shin, *Gwangju*



Spain

Matilde Canelles, *Granada*
Slaven Erceg, *Seville*
Pedro Cosme Redondo Liberal, *Cáceres*
Julian Pardo, *Zaragoza*
Josep-Maria Ribera, *Badalona*
Juan M Zapata, *Madrid*



Thailand

Chirayu Udomsakdi Auewarakul, *Bangkok*



Turkey

Mutay Aslan, *Antalya*
Murat Biteker, *Istanbul*
Taner Demirer, *Ankara*
Selami Kocak Toprak, *Ankara*
Ertan Yetkin, *Mersin*



United Kingdom

Dominique Bonnet, *London*
Olga Tura Ceide, *Edinburgh*
Helen A Ireland, *London*
Charles Henderson Lawrie, *Oxford*
Drew Provan, *London*
Dipak Purshottam Ramji, *Cardiff*
Sabrina Tosi, *Uxbridge*

Shao-An Xue, *London*
Jian guo Zhuang, *Liverpool*



United States

Ivo Abraham, *Tucson*
Julia E Brittain, *Chapel Hill*
Chung-Che Chang, *Houston*
Edward Alan Copelan, *Cleveland*
Zeev Estrov, *Houston*
Steve Fiering, *Lebanon*
Suzanne T Ildstad, *Louisville*
Elias Jabbour, *Houston*
Ming Jiang, *Nashville*
Katsuhiko Kita, *Galveston*
Robert G Lerner, *Valhalla*
Shaoguang Li, *Worcester*
Dazhi Liu, *Sacramento*
Ming-Lin Liu, *Philadelphia*
Surya Nauli, *Toledo*
Steffan Nawrocki, *San Antonio*
Xuyang Peng, *Nashville*
Manuel L Penichet, *Los Angeles*
Luis Francisco Porrata, *Rochester*
Rehan Qayyum, *Baltimore*
L Vijaya Mohan Rao, *San Diego*
Guangwen Ren, *New Brunswick*
Xiaoping Ren, *Cincinnati*
Jatin J Shah, *Houston*
Angus M Sinclair, *Thousand Oaks*
Ali A Sovari, *Chicago*
Christopher A Tormey, *New Haven*
Olga Volpert, *Chicago*
Zack Zhengyu Wang, *Scarborough*
EllenLori Weisberg, *Boston*
Wen-Shu Wu, *Scarborough*
Yi Wu, *Newark*
Feng-Chun Yang, *Indiana*
Karina Yazdanbakhsh, *New York*
Xin-Fu Zhou, *Adelaide*



MINIREVIEW

1

Bone marrow cell death and proliferation: Controlling mechanisms in normal and leukemic state

Kurata M, Suzuki S, Abe S, Onishi I, Kitagawa M

Contents

World Journal of Hematology
Volume 2 Number 1 February 6, 2013

APPENDIX I-V Instructions to authors

ABOUT COVER Editorial Board Member of *World Journal of Hematology*, Zeev Estrov, MD, Professor of Medicine, Department of Leukemia, 1515 Holcombe Blvd., Unit 0428, Houston, TX 77030, United States

AIM AND SCOPE

World Journal of Hematology (*World J Hematol*, *WJH*, online ISSN 2218-6204, DOI: 10.5315) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

WJH covers topics concerning experimental, clinical, oncological and transplant hematology, transfusion science, hemostasis and thrombosis, evidence-based medicine, epidemiology and nursing. Priority publication will be given to articles concerning diagnosis and treatment of hematological diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

INDEXING/ABSTRACTING *World Journal of Hematology* is now indexed in Digital Object Identifier.

FLYLEAF I-II Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Shuai Ma*
Responsible Electronic Editor: *Xiao-Mei Zheng*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xin-Xia Song*

NAME OF JOURNAL
World Journal of Hematology

ISSN
ISSN 2218-6204 (online)

LAUNCH DATE
June 6, 2012

FREQUENCY
Quarterly

EDITOR-IN-CHIEF
Xiaoyan Jiang, MD, PhD, Associate Professor, Medical Genetics, University of British Columbia, Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada

Thomas J Kipps, MD, PhD, Professor of Medicine, University of California, San Diego, Moores Cancer Center, 3855 Health Sciences Drive, MC 0820, La Jolla, CA 92093-0820, United States

EDITORIAL OFFICE
Jin-Lei Wang, Director
Xiu-Xia Song, Vice Director
World Journal of Hematology
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-85381891
Fax: +86-10-85381893
E-mail: wjhematol@wjgnet.com
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Co., Limited
Flat C, 23/F, Lucky Plaza,
315-321 Lockhart Road, Wan Chai,
Hong Kong, China
Fax: +852-6555-7188
Telephone: +852-3177-9906
E-mail: bpgooffice@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE
February 6, 2013

COPYRIGHT
© 2013 Baishideng. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/2218-6204/g_info_20100722173604.htm.

ONLINE SUBMISSION
<http://www.wjgnet.com/esp/>

Bone marrow cell death and proliferation: Controlling mechanisms in normal and leukemic state

Morito Kurata, Shiho Suzuki, Shinya Abe, Ichiroh Onishi, Masanobu Kitagawa

Morito Kurata, Shiho Suzuki, Shinya Abe, Ichiroh Onishi, Masanobu Kitagawa, Department of Comprehensive Pathology, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan

Author contributions: Suzuki S, Abe S and Onishi I offered suggestions regarding the conduct of the manuscript; Kurata M and Kitagawa M wrote the manuscript.

Correspondence to: Masanobu Kitagawa, MD, PhD, Professor, Chair, Department of Comprehensive Pathology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. masa.pth2@tmd.ac.jp

Telephone: +81-3-58035173 Fax: +81-3-58030123

Received: June 22, 2012 Revised: November 30, 2012

Accepted: January 5, 2013

Published online: February 6, 2013

Abstract

Bone marrow cell death and proliferation are regulated by multiple factors including genetic and epigenetic alterations of hematopoietic cells, crosstalk of hematopoietic cells with bone marrow mesenchymal cells through direct cell-cell interaction or cytokine/chemokine production, vascularity of the bone marrow, and interactions of sympathetic nerve system with hematopoiesis. Cell proliferation usually predominates over cell death in neoplastic processes such as leukemia and myeloproliferative neoplasms, while apoptotic processes also have a significant role in the pathogenesis of myelodysplastic syndromes. Recently, hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs) have been identified and their characters on self renewal process, differentiation, cell dynamics and drug resistance have been implicated. Although most leukemia cells are initially sensitive to chemo- or radiotherapy, LSCs are resistant and considered to be the basis for disease relapse after initial response. HSCs and LSCs may use similar interactions with bone marrow microenvironment. However, bone marrow microenvironment called niche should influence the normal as well as malignant hematopoiesis in different manners. Recent studies

have expanded the number of cell types constituting bone marrow niche and made the issue more complex. Since the majority of excellent and contributing studies on bone marrow niches have been performed in animal models, niches in human tissues are beginning to be localized and characterized. In this article, we summarize the relation of hematopoietic cells with niches and hope to point a hint to the novel strategy for treatment of malignant proliferation of hematopoietic cells.

© 2013 Baishideng. All rights reserved.

Key words: Bone marrow; Hematopoietic stem cells; Niche; Apoptosis; Leukemia

Kurata M, Suzuki S, Abe S, Onishi I, Kitagawa M. Bone marrow cell death and proliferation: Controlling mechanisms in normal and leukemic state. *World J Hematol* 2013; 2(1): 1-5 Available from: URL: <http://www.wjgnet.com/2218-6204/full/v2/i1/1.htm> DOI: <http://dx.doi.org/10.5315/wjh.v2.i1.1>

INTRODUCTION

Cell dynamics of hematopoietic cells/leukemic cells may be regulated by multiple factors in the bone marrow. Recently, interactions of hematopoietic stem cells (HSCs) with the bone marrow microenvironment have been extensively studied mainly using animal models with genetic modification. Many signaling pathways such as CXCR4/CXCL12, Jagged/Notch, Wnt, Ang-1/Tie2, SCF, very late antigen-4 (VLA-4), VCAM-1, and TGF have been shown to regulate the self-renewal, differentiation, proliferation, and apoptosis/senescence of HSCs^[1-11]. Mechanisms of crosstalk between hematopoietic cells and the bone marrow microenvironment would be closely associated with the pathogenesis of hematologic diseases including malignancies. Although leukemia cells are thought to harbor cell-autonomous mutations, the interaction with the microenvironment should play an important role

in the regulation of leukemia cell dynamics^[12]. This article reiterates the importance of mechanisms affecting the functions of the bone marrow microenvironment on the proliferation/apoptosis of hematopoietic/leukemia cells.

HSCS AND THEIR NICHE

The HSCs have two opposing characters - maintenance of an undifferentiated state analogous to pluripotent stem cells, and the execution of tissue-specific hematopoietic functions^[13]. In the bone marrow, characters of HSCs are maintained within a special microenvironment called a niche. The concept of niches was proposed in the 1970s; however, the nature and function of these stromal structures remains unclear. HSCs are in contact with bone-lining osteoblastic cells, but only a part of the HSCs seem to be located in this endosteal niche region. Instead, many HSCs are found in association with the sinusoidal endothelium, referred to as the vascular niche. However, osteoblast depletion results in extramedullary hematopoiesis, suggesting that a vascular niche alone is not sufficient to maintain hematopoiesis^[14]. Endosteal and vascular niches might regulate different HSC populations, although recent data depicts a more complicated feature, with functional crosstalk between cells in these two regions^[12,15,16].

Recently it was suggested that primitive mesenchymal cells, including CXCL12-abundant reticular cells^[17-20], nestin-expressing cells with sympathetic nerve system^[21-23], nonmyelinating Schwann cells^[24] and macrophages^[25,26] act as bone marrow niche-associated cells. The interactions between CXCR4 and CXCL12 (SDF-1) are especially important in the localization and retention of HSCs in the bone marrow. Furthermore, chemokine interactions through CXCL12 can cause the up-regulation of vascular cell adhesion molecule-1 and VLA-4 expression^[27]. CXCL12 also has an essential role in colonization of the bone marrow by HSCs during early development, because CXCL12-deficient embryos have severely reduced HSC numbers and a disturbed function^[28]. Further studies on the interplay of such regulatory forces as “cell fate and localization determinant” will likely shed light on the pathogenesis of hematological diseases.

BONE MARROW NICHES IN HEMATOPOIETIC PATHOLOGY

Recent animal model studies have provided insights into the role of aberrant microenvironment signaling leading to the pathogenesis of hematological diseases. Perturbations in niche signaling in murine models^[29] can mimic idiopathic myelofibrosis, leading to enhanced stem cell mobilization and the creation of alternate niches^[30]. The deletion of the *Dicer1* gene specifically in mouse osteoblasts (endosteal niches) disrupted the integrity of hematopoiesis. Myelodysplastic syndromes (MDS)-like phenotypes emerged in spite of the fact that hematopoietic cells had an intact *Dicer1*^[31]. Therefore, perturbation of specific mesenchymal stromal cells can cause disorder in the differentiation, proliferation, and apoptosis of hematopoietic

cells. In this mouse model, acute myeloid leukemia (AML) emerged with several acquired genetic abnormalities, supporting the concept of niche-induced leukemogenesis. Also, in human samples, the impaired expression of *DIC-ER*-associated genes was demonstrated in mesenchymal stromal cells from MDS patients^[32].

Concerning the bone marrow cell dynamics in MDS, excessive apoptosis of hematopoietic cells was observed to be induced by the bone marrow microenvironment^[33-48]. The apoptosis was mediated by paracrine as well as autocrine factors, implicating both medullary stromal cells and hematopoietic cells in the pathology of the disease. Pro-inflammatory cytokines such as tumor necrosis factor in the bone marrow microenvironment are mainly paracrine mediators of apoptosis. As autocrine stimulation mechanisms, it has recently been shown that the deregulation of ribosome biogenesis can initiate a stress response in hematopoietic cells through the p53-mediated signaling pathway. Thus, both the stromal cells of the bone marrow microenvironment and hematopoietic cells themselves possess a common and characteristic biology in this heterogeneous disease entity.

In human samples, the microenvironment has also been studied in multiple myeloma^[49]. Self-renewal pathway activation in the niche (such as the canonical Wnt pathway) has been postulated to result in enhanced myeloma cell survival^[50]. Another example of microenvironment-associated disease is the WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome. This rare syndrome is known to exhibit congenital neutropenia often caused by mutations in CXCR4 with increased sensitivity to CXCL12^[51].

LEUKEMIA STEM CELLS AND NICHES

Like many cancers, AML has been identified as a cell autonomous disorder. Namely, the genetic events leading to transformation of the normal hematopoietic cell are found within leukemia cells and are necessary and sufficient for the generation of leukemia. However, many studies have demonstrated evidence of functional heterogeneity among AML cells. In particular, there seems to be a subpopulation of AML cells referred to as “leukemia stem cells” (LSCs) that alone have long-term repopulating potential and the ability to propagate and maintain the AML phenotype^[52]. To understand the difference of LSCs from HSCs, clarification of the crosstalk between LSCs and niches would be very important. Niche-mediated mechanisms promote the engraftment and survival of LSCs. The biology of LSCs has been determined by studies of primary human AML cells transplanted into NOD-SCID or NOD-SCID IL2Rγ^{null} mice^[53,54]. In these xenograft models, AML cells have a phenotypic hierarchy, which parallels that of normal hematopoietic stem/progenitor cells^[1,55-58]. For example, the CD34⁺CD38⁻ AML population could engraft efficiently in NOD-SCID mice, but the more differentiated CD34⁺CD38⁺ and CD34⁻ AML cells were unable to engraft and yield colony-forming progenitors. Human AML cells preferentially engrafted in

the bone marrow endosteal region in NOD-SCID IL2R^{null} mice, and remained adjacent to bone marrow osteoblasts for up to 4 mo following transplantation^[54]. Homing to the microenvironment appears important in sustaining the survival of LSCs. Moreover, these cells were highly enriched for quiescent cells and were resistant to cytosine arabinoside chemotherapy^[59].

CROSSTALK OF LSCS WITH NICHES

Next, the specific mechanisms of niches regulating LSC fate should be clarified^[60]. For example, the interaction between CXCR4 and CXCL12 is known to regulate normal HSC proliferation and survival^[61-63]. What is the case in LSCs? Actually, CXCR4 is also expressed on primary leukemic cells, and high-level expression of CXCR4 on AML cells is a negative prognostic factor of relapse-free and overall survival^[64,65]. Treatment with the CXCR4 antagonist was shown to inhibit stromal cell-induced proliferative signals in AML cells and to increase the sensitivity to chemotherapy, resulting in the extended survival of AML-transplanted mice compared with treatment with chemotherapy alone^[66]. These data suggest that LSCs possess a CXCR4-dependent homing capacity that is analogous to normal hematopoietic cells, and antagonism of the CXCR4/CXCL12 axis is a logical therapeutic strategy for the treatment of acute leukemia.

However LSCs are rather heterogeneous. Even in LSCs, different patterns of interactions with niches were identified^[67]. The homing of pre-LSCs was similar to long-term HSCs, while the homing of established LSCs was most similar to that of committed myeloid progenitor and distinct from HSCs.

After homing to the bone marrow niches, leukemia cells are retained in these niches through cellular adhesion molecules such as VLA-4 and LFA-1 integrins^[68]. Increased VLA-4 expression has been demonstrated to correlate with increased bone marrow blast counts in AML^[69]. Furthermore, VLA-4-highly expressing AML cells show relative resistance to chemotherapy-induced apoptosis, and the administration of VLA-4 neutralizing antibodies inhibits this resistance^[70].

On the other hand, the leukemia cells were able to directly modulate the niche at the expense of normal hematopoietic stem and progenitor cells by down-regulating CXCL12 levels in areas of leukemia infiltration^[71]. It has been shown that stem cell factor, a niche regulator, was secreted by the leukemia cells, leading to the abnormal retention and engraftment of normal HSCs in the microenvironment with leukemic infiltration. Thus, identifying the mechanisms involved in the generation of various signals by HSCs, LSCs, and niches might provide new insights into the pathogenesis of acute leukemia as well as MDS and myeloproliferative neoplasms.

REFERENCES

- 1 Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. *Blood* 2009; **114**: 1150-1157 [PMID: 19401558 DOI: 10.1182/

- blood-2009-01-202606]
- 2 Lilly AJ, Johnson WE, Bunce CM. The haematopoietic stem cell niche: new insights into the mechanisms regulating haematopoietic stem cell behaviour. *Stem Cells Int* 2011; **2011**: 274564 [PMID: 22135682 DOI: 10.4061/2011/274564]
- 3 Oh IH, Humphries RK. Concise review: Multidimensional regulation of the hematopoietic stem cell state. *Stem Cells* 2012; **30**: 82-88 [PMID: 22083966 DOI: 10.1002/stem.776]
- 4 Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. *Leukemia* 2012; **26**: 54-62 [PMID: 21886170 DOI: 10.1038/leu.2011.236]
- 5 Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 1996; **382**: 635-638 [PMID: 8757135 DOI: 10.1038/382635a0]
- 6 Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. *Nature* 1998; **393**: 595-599 [PMID: 9634238 DOI: 10.1038/31269]
- 7 Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T, Hatzfeld A, Hatzfeld JA. TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. *J Cell Sci* 2000; **113** (Pt 3): 383-390 [PMID: 10639326]
- 8 Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell* 2004; **118**: 149-161 [PMID: 15260986 DOI: 10.1016/j.cell.2004.07.004]
- 9 Mancini SJ, Mantei N, Dumortier A, Suter U, MacDonald HR, Radtke F. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. *Blood* 2005; **105**: 2340-2342 [PMID: 15550486 DOI: 10.1182/blood-2004-08-3207]
- 10 Maillard I, Koch U, Dumortier A, Shestova O, Xu L, Sai H, Pross SE, Aster JC, Bhandoola A, Radtke F, Pear WS. Canonical notch signaling is dispensable for the maintenance of adult hematopoietic stem cells. *Cell Stem Cell* 2008; **2**: 356-366 [PMID: 18397755 DOI: 10.1016/j.stem.2008.02.011]
- 11 Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M, Witte L, May C, Shawber C, Kimura Y, Kitajewski J, Rosenwaks Z, Bernstein ID, Rafii S. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. *Cell Stem Cell* 2010; **6**: 251-264 [PMID: 20207228 DOI: 10.1016/j.stem.2010.02.001]
- 12 Vas V, Wandhoff C, Dörr K, Niebel A, Geiger H. Contribution of an aged microenvironment to aging-associated myeloproliferative disease. *PLoS One* 2012; **7**: e31523 [PMID: 22363661 DOI: 10.1371/journal.pone.0031523]
- 13 Forsberg EC, Passequé E, Prohaska SS, Wagers AJ, Koeva M, Stuart JM, Weissman IL. Molecular signatures of quiescent, mobilized and leukemia-initiating hematopoietic stem cells. *PLoS One* 2010; **5**: e8785 [PMID: 20098702 DOI: 10.1371/journal.pone.0008785]
- 14 Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. *Blood* 2004; **103**: 3258-3264 [PMID: 14726388 DOI: 10.1182/blood-2003-11-4011]
- 15 Lo Celso C, Fleming HE, Wu JW, Zhao CX, Mlake-Lye S, Fujisaki J, Côté D, Rowe DW, Lin CP, Scadden DT. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. *Nature* 2009; **457**: 92-96 [PMID: 19052546 DOI: 10.1038/nature07434]
- 16 Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. *J Exp Med* 2011; **208**: 421-428 [PMID: 21402747 DOI: 10.1084/jem.20110132]
- 17 Nagasawa T, Omatsu Y, Sugiyama T. Control of hematopoietic stem cells by the bone marrow stromal niche: the role

- of reticular cells. *Trends Immunol* 2011; **32**: 315-320 [PMID: 21531624 DOI: 10.1016/j.it.2011.03.009]
- 18 **Kiel MJ**, Morrison SJ. Maintaining hematopoietic stem cells in the vascular niche. *Immunity* 2006; **25**: 862-864 [PMID: 17174928 DOI: 10.1016/j.immuni.2006.11.005]
 - 19 **Sugiyama T**, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity* 2006; **25**: 977-988 [PMID: 17174120 DOI: 10.1016/j.immuni.2006.10.016]
 - 20 **Sugiyama T**, Nagasawa T. Bone marrow niches for hematopoietic stem cells and immune cells. *Inflamm Allergy Drug Targets* 2012; **11**: 201-206 [PMID: 22452607]
 - 21 **Méndez-Ferrer S**, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma'ayan A, Enikolopov GN, Frenette PS. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature* 2010; **466**: 829-834 [PMID: 20703299 DOI: 10.1038/nature09262]
 - 22 **Katayama Y**, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 2006; **124**: 407-421 [PMID: 16439213 DOI: 10.1016/j.cell.2005.10.041]
 - 23 **Méndez-Ferrer S**, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. *Nature* 2008; **452**: 442-447 [PMID: 18256599 DOI: 10.1038/nature06685]
 - 24 **Yamazaki S**, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S, Iwama A, Nakauchi H. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. *Cell* 2011; **147**: 1146-1158 [PMID: 22118468 DOI: 10.1016/j.cell.2011.09.053]
 - 25 **Winkler IG**, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, Poulton JJ, van Rooijen N, Alexander KA, Raggett LJ, Lévesque JP. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. *Blood* 2010; **116**: 4815-4828 [PMID: 20713966 DOI: 10.1182/blood-2009-11-253534]
 - 26 **Chow A**, Lucas D, Hidalgo A, Méndez-Ferrer S, Hashimoto D, Scheiermann C, Battista M, Leboeuf M, Prophete C, van Rooijen N, Tanaka M, Merad M, Frenette PS. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. *J Exp Med* 2011; **208**: 261-271 [PMID: 21282381 DOI: 10.1084/jem.20101688]
 - 27 **Avecilla ST**, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, de Sauvage F, Rafii S. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. *Nat Med* 2004; **10**: 64-71 [PMID: 14702636 DOI: 10.1038/nm973]
 - 28 **Ara T**, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. *Immunity* 2003; **19**: 257-267 [PMID: 12932359 DOI: 10.1016/S1074-7613(03)00201-2]
 - 29 **Walkley CR**, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, Westmoreland SV, Chambon P, Scadden DT, Purton LE. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. *Cell* 2007; **129**: 1097-1110 [PMID: 17574023 DOI: 10.1016/j.cell.2007.05.014]
 - 30 **Lataillade JJ**, Pierre-Louis O, Hasselbalch HC, Uzan G, Jamin C, Martyré MC, Le Bousse-Kerdilès MC. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. *Blood* 2008; **112**: 3026-3035 [PMID: 18669872 DOI: 10.1182/blood-2008-06-158386]
 - 31 **Raaijmakers MH**, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA, Ebert BL, Al-Shahrour F, Hasserjian RP, Scadden EO, Aung Z, Matza M, Merkenschlager M, Lin C, Rommens JM, Scadden DT. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. *Nature* 2010; **464**: 852-857 [PMID: 20305640 DOI: 10.1038/nature08851]
 - 32 **Santamaría C**, Muntión S, Rosón B, Blanco B, López-Villar O, Carrancio S, Sánchez-Guijo FM, Díez-Campelo M, Alvarez-Fernández S, Sarasquete ME, de las Rivas J, González M, San Miguel JF, Del Cañizo MC. Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. *Haematologica* 2012; **97**: 1218-1224 [PMID: 22371183 DOI: 10.3324/haematol.2011.054437]
 - 33 **Kitagawa M**, Kurata M, Yamamoto K, Abe S, Suzuki S, Umeda S. Molecular pathology of myelodysplastic syndromes: biology of medullary stromal and hematopoietic cells (review). *Mol Med Rep* 2011; **4**: 591-596 [PMID: 21584497 DOI: 10.3892/mmr.2011.493]
 - 34 **Kitagawa M**, Kamiyama R, Kasuga T. Expression of the proliferating cell nuclear antigen in bone marrow cells from patients with myelodysplastic syndromes and aplastic anemia. *Hum Pathol* 1993; **24**: 359-363 [PMID: 8098317]
 - 35 **Kitagawa M**, Yoshida S, Kuwata T, Tanizawa T, Kamiyama R. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia. *Am J Pathol* 1994; **145**: 338-344 [PMID: 8053492]
 - 36 **Kitagawa M**, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. *Leukemia* 1997; **11**: 2049-2054 [PMID: 9447819]
 - 37 **Kitagawa M**, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. *Leukemia* 1998; **12**: 486-492 [PMID: 9557605]
 - 38 **Kitagawa M**, Takahashi M, Yamaguchi S, Inoue M, Ogawa S, Hirokawa K, Kamiyama R. Expression of inducible nitric oxide synthase (NOS) in bone marrow cells of myelodysplastic syndromes. *Leukemia* 1999; **13**: 699-703 [PMID: 10374872]
 - 39 **Mundle SD**, Ali A, Cartledge JD, Reza S, Alvi S, Showel MM, Mative BY, Shetty VT, Venugopal P, Gregory SA, Raza A. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. *Am J Hematol* 1999; **60**: 36-47 [PMID: 9883804]
 - 40 **Mundle SD**, Reza S, Ali A, Mative Y, Shetty V, Venugopal P, Gregory SA, Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. *Cancer Lett* 1999; **140**: 201-207 [PMID: 10403560]
 - 41 **Allampallam K**, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh MW, York A, Raza A. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. *Int J Hematol* 2002; **75**: 289-297 [PMID: 11999358]
 - 42 **Sawanobori M**, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R, Hirokawa K, Kitagawa M. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. *Leuk Res* 2003; **27**: 583-591 [PMID: 12681357 DOI: 10.1016/S0145-2126(02)00095-4]
 - 43 **Yamamoto K**, Abe S, Nakagawa Y, Suzuki K, Hasegawa M, Inoue M, Kurata M, Hirokawa K, Kitagawa M. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. *Leuk Res* 2004; **28**: 1203-1211 [PMID: 15380346 DOI: 10.1016/j.leukres.2004.03.020]
 - 44 **Kurata M**, Hasegawa M, Nakagawa Y, Abe S, Yamamoto K, Suzuki K, Kitagawa M. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. *Exp Mol Pathol* 2006; **81**: 249-254 [PMID: 16566920 DOI: 10.1016/j.yexmp.2006.01.004]

- 45 **Bourne JR**, Jagannathan V, Giese B, Ward JW. A software system for syntactic analysis of the EEG. *Comput Programs Biomed* 1980; **11**: 190-200 [PMID: 7408459 DOI: 10.1111/j.1365-2141.2007.06539.x]
- 46 **Kuninaka N**, Kurata M, Yamamoto K, Suzuki S, Umeda S, Kirimura S, Arai A, Nakagawa Y, Suzuki K, Kitagawa M. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. *Exp Mol Pathol* 2010; **88**: 293-298 [PMID: 20132814 DOI: 10.1016/j.yexmp.2010.01.009]
- 47 **Raza A**, Cruz R, Latif T, Mukherjee S, Galili N. The biology of myelodysplastic syndromes: unity despite heterogeneity. *Hematol Rep* 2010; **2**: e4 [PMID: 22184517 DOI: 10.4081/hr.2010.e4]
- 48 **Suzuki S**, Kurata M, Abe S, Miyazawa R, Murayama T, Hidaka M, Yamamoto K, Kitagawa M. Overexpression of MCM2 in myelodysplastic syndromes: association with bone marrow cell apoptosis and peripheral cytopenia. *Exp Mol Pathol* 2012; **92**: 160-166 [PMID: 22115939 DOI: 10.1016/j.yexmp.2011.11.003]
- 49 **Podar K**, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. *Leukemia* 2009; **23**: 10-24 [PMID: 18843284 DOI: 10.1038/leu.2008.259]
- 50 **Derksen PW**, Tjin E, Meijer HP, Klok MD, MacGillivray HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. *Proc Natl Acad Sci USA* 2004; **101**: 6122-6127 [PMID: 15067127 DOI: 10.1073/pnas.0305855101]
- 51 **Kawai T**, Choi U, Cardwell L, DeRavin SS, Naumann N, Whiting-Theobald NL, Linton GF, Moon J, Murphy PM, Malech HL. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. *Blood* 2007; **109**: 78-84 [PMID: 16946301 DOI: 10.1182/blood-2006-05-025296]
- 52 **Kikushige Y**, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, Akashi K. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. *Cell Stem Cell* 2010; **7**: 708-717 [PMID: 21112565 DOI: 10.1016/j.stem.2010.11.014]
- 53 **Somervaille TC**, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. *Cancer Cell* 2006; **10**: 257-268 [PMID: 17045204 DOI: 10.1016/j.ccr.2006.08.020]
- 54 **Ishikawa F**, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. *Nat Biotechnol* 2007; **25**: 1315-1321 [PMID: 17952057 DOI: 10.1038/nbt1350]
- 55 **Lapidot T**, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994; **367**: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]
- 56 **Hope KJ**, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. *Nat Immunol* 2004; **5**: 738-743 [PMID: 15170211 DOI: 10.1038/ni1080]
- 57 **Buss EC**, Ho AD. Leukemia stem cells. *Int J Cancer* 2011; **129**: 2328-2336 [PMID: 21796620 DOI: 10.1002/ijc.26318]
- 58 **Becker MW**, Jordan CT. Leukemia stem cells in 2010: current understanding and future directions. *Blood Rev* 2011; **25**: 75-81 [PMID: 21216511 DOI: 10.1016/j.blre.2010.11.001]
- 59 **Arai F**, Suda T. Regulation of hematopoietic stem cells in the osteoblastic niche. *Adv Exp Med Biol* 2007; **602**: 61-67 [PMID: 17966389]
- 60 **Raaijmakers MH**. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. *Haematologica* 2011; **96**: 1041-1048 [PMID: 21459792 DOI: 10.3324/haematol.2010.028035]
- 61 **Peled A**, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, Nagler A, Ben-Hur H, Many A, Shultz L, Lider O, Alon R, Zipori D, Lapidot T. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science* 1999; **283**: 845-848 [PMID: 9933168 DOI: 10.1126/science.283.5403.845]
- 62 **Avigdor A**, Goichberg P, Shvitiel S, Dar A, Peled A, Samira S, Kollet O, Hershkovich R, Alon R, Hardan I, Ben-Hur H, Naor D, Nagler A, Lapidot T. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. *Blood* 2004; **103**: 2981-2989 [PMID: 15070674 DOI: 10.1182/blood-2003-10-3611]
- 63 **Lapidot T**, Dar A, Kollet O. How do stem cells find their way home? *Blood* 2005; **106**: 1901-1910 [PMID: 15890683 DOI: 10.1182/blood-2005-04-1417]
- 64 **Rombouts EJ**, Pavic B, Löwenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. *Blood* 2004; **104**: 550-557 [PMID: 15054042 DOI: 10.1182/blood-2004-02-0566]
- 65 **Spoer AC**, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. *Blood* 2007; **109**: 786-791 [PMID: 16888090 DOI: 10.1182/blood-2006-05-024844]
- 66 **Nervi B**, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. *Blood* 2009; **113**: 6206-6214 [PMID: 19050309 DOI: 10.1182/blood-2008-06-162123]
- 67 **Lane SW**, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA. Differential niche and Wnt requirements during acute myeloid leukemia progression. *Blood* 2011; **118**: 2849-2856 [PMID: 21765021 DOI: 10.1182/blood-2011-03-345165]
- 68 **Reuss-Borst MA**, Klein G, Waller HD, Müller CA. Differential expression of adhesion molecules in acute leukemia. *Leukemia* 1995; **9**: 869-874 [PMID: 7539515]
- 69 **Jin L**, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. *Nat Med* 2006; **12**: 1167-1174 [PMID: 16998484 DOI: 10.1038/nm1483]
- 70 **Matsunaga T**, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, Akiyama T, Kuroda H, Kawano Y, Kobune M, Kato J, Hirayama Y, Sakamaki S, Kohda K, Miyake K, Niitsu Y. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. *Nat Med* 2003; **9**: 1158-1165 [PMID: 12897778 DOI: 10.1038/nm909]
- 71 **Colmone A**, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. *Science* 2008; **322**: 1861-1865 [PMID: 19095944 DOI: 10.1126/science.1164390]

P- Reviewers Bonnet D, Fukuda S, Poggi A

S- Editor Song XX L- Editor A E- Editor Zheng XM





INSTRUCTIONS TO AUTHORS

GENERAL INFORMATION

World Journal of Hematology (*World J Hematol*, *WJH*, online ISSN 2218-6204, DOI: 10.5315) is a peer-reviewed open access (OA) academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

Aim and scope

WJH covers topics concerning experimental, clinical, oncological and transplant hematology, transfusion science, hemostasis and thrombosis, evidence-based medicine, epidemiology and nursing. The current columns of *WJH* include editorial, frontier, diagnostic advances, therapeutics advances, field of vision, mini-reviews, review, topic highlight, medical ethics, original articles, case report, clinical case conference (Clinicopathological conference), and autobiography. Priority publication will be given to articles concerning diagnosis and treatment of hematological diseases. The following aspects are covered: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

We encourage authors to submit their manuscripts to *WJH*. We will give priority to manuscripts that are supported by major national and international foundations and those that are of great basic and clinical significance.

WJH is edited and published by Baishideng Publishing Group (BPG). BPG has a strong professional editorial team composed of science editors, language editors and electronic editors. BPG currently publishes 42 OA clinical medical journals, including 41 in English, has a total of 15 471 editorial board members or peer reviewers, and is a world first-class publisher.

Columns

The columns in the issues of *WJH* will include: (1) Editorial: The editorial board members are invited to make comments on an important topic in their field in terms of its current research status and future directions to lead the development of this discipline; (2) Frontier: The editorial board members are invited to select a highly cited cutting-edge original paper of his/her own to summarize major findings, the problems that have been resolved and remain to be resolved, and future research directions to help readers understand his/her important academic point of view and future research directions in the field; (3) Diagnostic Advances: The editorial board members are invited to write high-quality diagnostic advances in their field to improve the diagnostic skills of readers. The topic covers general clinical diagnosis, differential diagnosis, pathological diagnosis, laboratory diagnosis, imaging diagnosis, endoscopic diagnosis, biotechnological diagnosis, functional diagnosis, and physical diagnosis; (4) Therapeutics Advances: The editorial board members are invited to write high-quality therapeutic advances in their field to help improve the therapeutic skills of readers. The topic covers medication therapy, psychotherapy, physical therapy, replacement therapy, interventional therapy, minimally invasive therapy, endoscopic therapy, transplantation therapy, and surgical therapy; (5) Field of Vision: The editorial board members are invited to write commentaries on classic articles, hot topic articles, or latest articles to keep readers at the forefront of research and increase their levels of clinical research. Classic articles refer to papers that are included

in Web of Knowledge and have received a large number of citations (ranking in the top 1%) after being published for more than years, reflecting the quality and impact of papers. Hot topic articles refer to papers that are included in Web of Knowledge and have received a large number of citations after being published for no more than 2 years, reflecting cutting-edge trends in scientific research. Latest articles refer to the latest published high-quality papers that are included in PubMed, reflecting the latest research trends. These commentary articles should focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions. Basic information about the article to be commented (including authors, article title, journal name, year, volume, and inclusive page numbers); (6) Minireviews: The editorial board members are invited to write short reviews on recent advances and trends in research of molecular biology, genomics, and related cutting-edge technologies to provide readers with the latest knowledge and help improve their diagnostic and therapeutic skills; (7) Review: To make a systematic review to focus on the status quo of research, the most important research topics, the problems that have now been resolved and remain to be resolved, and future research directions; (8) Topic Highlight: The editorial board members are invited to write a series of articles (7-10 articles) to comment and discuss a hot topic to help improve the diagnostic and therapeutic skills of readers; (9) Medical Ethics: The editorial board members are invited to write articles about medical ethics to increase readers' knowledge of medical ethics. The topic covers international ethics guidelines, animal studies, clinical trials, organ transplantation, etc.; (10) Clinical Case Conference or Clinicopathological Conference: The editorial board members are invited to contribute high-quality clinical case conference; (11) Original Articles: To report innovative and original findings in hematology; (12) Brief Articles: To briefly report the novel and innovative findings in hematology; (13) Meta-Analysis: To evaluate the clinical effectiveness in hematology by using data from two or more randomised control trials; (14) Case Report: To report a rare or typical case; (15) Letters to the Editor: To discuss and make reply to the contributions published in *WJH*, or to introduce and comment on a controversial issue of general interest; (16) Book Reviews: To introduce and comment on quality monographs of hematology; and (17) Autobiography: The editorial board members are invited to write their autobiography to provide readers with stories of success or failure in their scientific research career. The topic covers their basic personal information and information about when they started doing research work, where and how they did research work, what they have achieved, and their lessons from success or failure.

Name of journal

World Journal of Hematology

ISSN

ISSN 2218-6204 (online)

Launch date

June 6, 2012

Frequency

Quarterly

Editor-in-Chief

Xiaoyan Jiang, MD, PhD, Associate Professor, Medical Gen-

Instructions to authors

etics, University of British Columbia, Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada

Thomas J Kipps, MD, PhD, Professor of Medicine, University of California, San Diego, Moores Cancer Center, 3855 Health Sciences Drive, MC 0820, La Jolla, CA 92093-0820, United States

Editorial office

Jin-Lei Wang, Director

Xiu-Xia Song, Vice Director

World Journal of Hematology

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-59080039

Fax: +86-10-85381893

E-mail: wjhematol@wjnet.com

<http://www.wjnet.com>

Publisher

Baishideng Publishing Group Co., Limited

Flat C, 23/F, Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Telephone: +852-58042046

Fax: +852-31158812

E-mail: bpgoffice@wjnet.com

<http://www.wjnet.com>

Production center

Beijing Baishideng BioMed Scientific Co., Limited

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

Representative office

USA Office

8226 Regency Drive,

Pleasanton, CA 94588-3144, United States

Instructions to authors

Full instructions are available online at http://www.wjnet.com/2218-6204/g_info_20100722173604.htm.

Indexed and Abstracted in

Digital Object Identifier.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJH* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copyedit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now

available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjnet.com/esps/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjnet.com/2218-6204/g_info_20100722173604.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjhematol@wjnet.com, or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g., Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Profes-

sor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g., Telephone: +86-10-85381892 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision on acceptance is made only when at least two experts recommend publication of an article. All peer-reviewers are acknowledged on Express Submission and Peer-review System website.

Abstract

There are unstructured abstracts (no less than 200 words) and structured abstracts. The specific requirements for structured abstracts are as follows:

An informative, structured abstract should accompany each manuscript. Abstracts of original contributions should be structured into the following sections: AIM (no more than 20 words; Only the purpose of the study should be included. Please write the Aim in the form of "To investigate/study/..."), METHODS (no less than 140 words for Original Articles; and no less than 80 words for Brief Articles), RESULTS (no less than 150 words for Original Articles and no less than 120 words for Brief Articles; You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g., 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$), and CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Core tip

Please write a summary of less than 100 words to outline the most innovative and important arguments and core contents in your paper to attract readers.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both.

Illustrations

Figures should be numbered as 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...etc. It is our principle to publish high resolution-figures for the E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, etc., and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. **P* <

Instructions to authors

0.05, ^b $P < 0.01$ should be noted ($P > 0.05$ should not be noted). If there are other series of P values, ^c $P < 0.05$ and ^d $P < 0.01$ are used. A third series of P values can be expressed as ^e $P < 0.05$ and ^f $P < 0.01$. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g., PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature

of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *ν* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose) 6.4 ± 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 $24.5 \mu\text{g/L}$; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: http://www.wjgnet.com/2218-6204/g_info_20100723213202.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

Examples for paper writing

All types of articles' writing style and requirement will be found in the link: <http://www.wjgnet.com/esps/NavigationInfo.aspx?id=15>

RESUBMISSION OF THE REVISED MANUSCRIPTS

Authors must revise their manuscript carefully according to the revision policies of Baishideng Publishing Group Co., Limited. The revised version, along with the signed copyright transfer agreement, responses to the reviewers, and English language Grade A certifi-

cate (for non-native speakers of English), should be submitted to the online system *via* the link contained in the e-mail sent by the editor. If you have any questions about the revision, please send e-mail to esps@wjgnet.com.

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2218-6204/g_info_20100723213049.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2218-6204/g_info_20100723212803.htm.

Proof of financial support

For papers supported by a foundation, authors should provide a copy of the approval document and serial number of the foundation.

Links to documents related to the manuscript

WJH will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Publication fee

WJH is an international, peer-reviewed, OA online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium and format, provided the original work is properly cited. The use is non-commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. Publication fee: 600 USD per article. All invited articles are published free of charge.



Published by **Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza, 315-321 Lockhart Road,

Wan Chai, Hong Kong, China

Fax: +852-31158812

Telephone: +852-58042046

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

